Residual DNA Size Analysis Kit-E.coli

Analysis of residual DNA in biopharmaceutical products is a critical aspect of ensuring product safety and efficacy. Residual DNA refers to small amounts of DNA that may remain from host cells used in the production of biopharmaceuticals. Regulatory agencies have placed strict limits on its presence due to concerns about potential carcinogenicity, viral transmission, and immunogenic responses. Specifically, regulatory agencies such as the FDA stipulate that the amount of residual host cell DNA in biopharmaceutical products should generally not exceed 10 ng per dose and should not exceed 200 base pairs in size. A common host organism used in recombinant protein production is Escherichia coli (E. coli), a Gram-negative bacterium that is widely used due to its rapid growth and well-characterized genetics. The Residual DNA Size Analysis Kit - E. coli is designed to accurately detect and characterize the size distribution of residual DNA from E. coli in biopharmaceutical products. Understanding the size distribution of residual DNA is critical because smaller DNA fragments (less than 200 base pairs) are less likely to be intact or contain entire genes and therefore present a lower risk.